Debbane Raymond 的 Form 4 申報
Crescent Biopharma, Inc.CBIO，2024/8/5 申報
- 申報編號
- 0000950170-24-090910
- 申報時間
- 2024/8/5 16:53 ET
- 交易日
- 2024/8/1-8/2
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 2 筆非衍生性交易。公開市場賣出合計 $7.11 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Debbane RaymondCIK 0001053890 | 持股 10% 以上大股東 |
| Invus Public Equities Advisors, LLCCIK 0001340096 | 持股 10% 以上大股東 |
| Invus Public Equities, L.P.CIK 0001340097 | 持股 10% 以上大股東 |
| Siren, L.L.C.CIK 0002005245 | 持股 10% 以上大股東 |
| Invus Global Management, LLCCIK 0002005369 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.2185 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.20 to $0.2025 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。